Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study
Identifieur interne : 002A13 ( Main/Exploration ); précédent : 002A12; suivant : 002A14Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study
Auteurs : W. Birkmayer [Autriche] ; J. Knoll [Hongrie] ; P. Riederer [Autriche] ; H. Youdim [Israël] ; Vera Hars [Hongrie] ; J. Marton [Hongrie]Source :
- Journal of Neural Transmission [ 0300-9564 ] ; 1985-06-01.
Abstract
Summary: In an open, uncontrolled study the longterm (9 years) effect of treatment with Madopar® alone (n=377) or in combination with l-deprenyl (selegiline, selective monoamine oxidase type B inhibitor) (n=564) have been compared in Parkinsonian patients. In patients who lost their response to conventional Madopar therapy the addition of l-deprenyl resulted in a significant recouping of levodopa effect. The survival analysis revealed a significant increase of life expectancy in Madopar-l-deprenyl group regardless of the fact whether or not the significant demographic differences between the two groups were taken into account. Although the mechanism underlying this action of l-deprenyl is not known, the results are interpreted as indicating l-deprenyl's ability to prevent or retard the degeneration of striatal dopaminergic neurons. l-Deprenyl is the first anti-Parkinson drug having such a property. This hypothesis is not far fetched since l-deprenyl selectively prevents the degeneration of striatal dopaminergic neurons induced in animals by the illicit drug l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Since latter compound is known to cause Parkinsonism in man and primates or Parkinson-like neurochemical and pathological changes in other animals the implications of the present study involving monoamine oxidase activity and l-deprenyl are apparent.
Url:
DOI: 10.1007/BF01245973
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study</title><author><name sortKey="Birkmayer, W" sort="Birkmayer, W" uniqKey="Birkmayer W" first="W." last="Birkmayer">W. Birkmayer</name></author><author><name sortKey="Knoll, J" sort="Knoll, J" uniqKey="Knoll J" first="J." last="Knoll">J. Knoll</name></author><author><name sortKey="Riederer, P" sort="Riederer, P" uniqKey="Riederer P" first="P." last="Riederer">P. Riederer</name></author><author><name sortKey="Youdim, H" sort="Youdim, H" uniqKey="Youdim H" first="H." last="Youdim">H. Youdim</name></author><author><name sortKey="Hars, Vera" sort="Hars, Vera" uniqKey="Hars V" first="Vera" last="Hars">Vera Hars</name></author><author><name sortKey="Marton, J" sort="Marton, J" uniqKey="Marton J" first="J." last="Marton">J. Marton</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:EFA5A4287789A1B61926A96341DA37B94CBF1735</idno><date when="1985" year="1985">1985</date><idno type="doi">10.1007/BF01245973</idno><idno type="url">https://api.istex.fr/document/EFA5A4287789A1B61926A96341DA37B94CBF1735/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000A27</idno><idno type="wicri:Area/Main/Curation">000897</idno><idno type="wicri:Area/Main/Exploration">002A13</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study</title><author><name sortKey="Birkmayer, W" sort="Birkmayer, W" uniqKey="Birkmayer W" first="W." last="Birkmayer">W. Birkmayer</name><affiliation wicri:level="3"><country xml:lang="fr">Autriche</country><wicri:regionArea>Evangelical Hospital, Rossauer Lände, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Knoll, J" sort="Knoll, J" uniqKey="Knoll J" first="J." last="Knoll">J. Knoll</name><affiliation wicri:level="3"><country xml:lang="fr">Hongrie</country><wicri:regionArea>Department of Pharmacology, Semmelweis University, Medical School, Budapest</wicri:regionArea><placeName><settlement type="city">Budapest</settlement><region nuts="2">Hongrie centrale</region></placeName></affiliation></author><author><name sortKey="Riederer, P" sort="Riederer, P" uniqKey="Riederer P" first="P." last="Riederer">P. Riederer</name><affiliation wicri:level="3"><country xml:lang="fr">Autriche</country><wicri:regionArea>Ludwig Boltzmann-Institute of Clinical Neurobiology, Neurochemistry Group, Lainz-Hospital, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Youdim, H" sort="Youdim, H" uniqKey="Youdim H" first="H." last="Youdim">H. Youdim</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Technion-Faculty of Medicine, Department of Pharmacology, Rappaport Family Research Institute, Haifa</wicri:regionArea><wicri:noRegion>Haifa</wicri:noRegion></affiliation></author><author><name sortKey="Hars, Vera" sort="Hars, Vera" uniqKey="Hars V" first="Vera" last="Hars">Vera Hars</name><affiliation wicri:level="3"><country xml:lang="fr">Hongrie</country><wicri:regionArea>Department of Clinical Research and Biometrics, Chinoin Pharmaceutical and Chemical Works, Ltd., Budapest</wicri:regionArea><placeName><settlement type="city">Budapest</settlement><region nuts="2">Hongrie centrale</region></placeName></affiliation></author><author><name sortKey="Marton, J" sort="Marton, J" uniqKey="Marton J" first="J." last="Marton">J. Marton</name><affiliation wicri:level="3"><country xml:lang="fr">Hongrie</country><wicri:regionArea>Department of Clinical Research and Biometrics, Chinoin Pharmaceutical and Chemical Works, Ltd., Budapest</wicri:regionArea><placeName><settlement type="city">Budapest</settlement><region nuts="2">Hongrie centrale</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neural Transmission</title><title level="j" type="sub">Basic neurosciences and genetics, Parkinson's disease and allied conditions, Alzheimer's disease and related disorders, biological psychiatry</title><title level="j" type="abbrev">J. Neural Transmission</title><idno type="ISSN">0300-9564</idno><idno type="eISSN">1435-1463</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Vienna</pubPlace><date type="published" when="1985-06-01">1985-06-01</date><biblScope unit="volume">64</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="113">113</biblScope><biblScope unit="page" to="127">127</biblScope></imprint><idno type="ISSN">0300-9564</idno></series><idno type="istex">EFA5A4287789A1B61926A96341DA37B94CBF1735</idno><idno type="DOI">10.1007/BF01245973</idno><idno type="ArticleID">Art4</idno><idno type="ArticleID">BF01245973</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0300-9564</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: In an open, uncontrolled study the longterm (9 years) effect of treatment with Madopar® alone (n=377) or in combination with l-deprenyl (selegiline, selective monoamine oxidase type B inhibitor) (n=564) have been compared in Parkinsonian patients. In patients who lost their response to conventional Madopar therapy the addition of l-deprenyl resulted in a significant recouping of levodopa effect. The survival analysis revealed a significant increase of life expectancy in Madopar-l-deprenyl group regardless of the fact whether or not the significant demographic differences between the two groups were taken into account. Although the mechanism underlying this action of l-deprenyl is not known, the results are interpreted as indicating l-deprenyl's ability to prevent or retard the degeneration of striatal dopaminergic neurons. l-Deprenyl is the first anti-Parkinson drug having such a property. This hypothesis is not far fetched since l-deprenyl selectively prevents the degeneration of striatal dopaminergic neurons induced in animals by the illicit drug l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Since latter compound is known to cause Parkinsonism in man and primates or Parkinson-like neurochemical and pathological changes in other animals the implications of the present study involving monoamine oxidase activity and l-deprenyl are apparent.</div></front></TEI><affiliations><list><country><li>Autriche</li><li>Hongrie</li><li>Israël</li></country><region><li>Hongrie centrale</li><li>Vienne (Autriche)</li></region><settlement><li>Budapest</li><li>Vienne (Autriche)</li></settlement></list><tree><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Birkmayer, W" sort="Birkmayer, W" uniqKey="Birkmayer W" first="W." last="Birkmayer">W. Birkmayer</name></region><name sortKey="Riederer, P" sort="Riederer, P" uniqKey="Riederer P" first="P." last="Riederer">P. Riederer</name></country><country name="Hongrie"><region name="Hongrie centrale"><name sortKey="Knoll, J" sort="Knoll, J" uniqKey="Knoll J" first="J." last="Knoll">J. Knoll</name></region><name sortKey="Hars, Vera" sort="Hars, Vera" uniqKey="Hars V" first="Vera" last="Hars">Vera Hars</name><name sortKey="Marton, J" sort="Marton, J" uniqKey="Marton J" first="J." last="Marton">J. Marton</name></country><country name="Israël"><noRegion><name sortKey="Youdim, H" sort="Youdim, H" uniqKey="Youdim H" first="H." last="Youdim">H. Youdim</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A13 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002A13 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:EFA5A4287789A1B61926A96341DA37B94CBF1735
|texte= Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study
}}
| This area was generated with Dilib version V0.6.23. |  |